Advertising disclosure: glp-1telemedicine.com earns commissions from some links. How we operate.
HomeBuyer's Guide › The Telehealth Watchlist: Our Live-Updated Scoring of Every Major GLP-1 Provider
Buyer's GuidePublished April 11, 2026glp-1telemedicine editorial team

The Telehealth Watchlist: Our Live-Updated Scoring of Every Major GLP-1 Provider

We maintain a Watchlist of every major GLP-1 telehealth provider, scored across the same criteria, updated continuously. This piece explains the methodology so you can interpret the Watchlist intelligently — and so you can apply the same framework to a provider we haven't yet covered.

The actual Watchlist lives on its own page, which is updated as new information emerges. This article is the methodology document.

Why a Watchlist exists

A static article goes stale. FDA issues a warning letter; a provider changes pharmacy partners; a state passes a new telehealth restriction; a company gets acquired. Any of these events changes a provider's scorecard within days. An annually-updated "best of" roundup is obsolete by the time it publishes.

The Watchlist is our attempt to solve this. It's a living scorecard with a version history. Providers are added, reviewed periodically, updated when material changes occur, and occasionally removed from active scoring if they shut down or radically change their model.

The composite score

Each provider on the Watchlist receives a composite score from 0 to 100, built from five weighted components. Each component is itself a sub-score with multiple inputs.

Component 1: Regulatory posture (25 points)

How clean is the provider's compliance record?

Component 2: Transparency (25 points)

How much is disclosed versus hidden?

Component 3: Clinical practices (20 points)

Is the medicine practiced well?

Component 4: Customer practices (15 points)

How does the company treat customers operationally?

Component 5: Reputation signal (15 points)

What does the broader record say?

How scores are interpreted

RangeTierRecommendation
85-100Highly recommendedStrong across all categories. Suitable for any patient who matches the clinical model.
70-84Recommended with notesStrong overall with specific caveats in our writeup. Good for most patients.
55-69Acceptable with caveatsWorkable for the right patient, but caveats are substantial. Read the writeup carefully.
40-54Consider alternativesSerious concerns in at least one category. Possibly workable but better options exist.
Below 40AvoidOur editors would not personally use this provider given current state.
DelistedShut down or transformedNo longer operating, or operating in a fundamentally different form.

Update cadence

Each provider on the Watchlist receives one of three review statuses:

The Watchlist page shows the last review date for each provider. Never treat a stale review as authoritative.

What triggers an immediate re-review

The following events trigger same-week re-review regardless of scheduled cadence:

What this methodology does not do

Transparency about limitations matters more than the score itself.

How to use the Watchlist effectively

  1. Start with tier. The 85+ and 70-84 tiers are where most patients should look first.
  2. Read the writeup, not just the score. Two providers can both score 75 for very different reasons. The writeup tells you which caveats apply to which provider.
  3. Check the last-review date. Reviews older than 6 months should be treated with more caution, especially for providers in the Active Monitoring category.
  4. Cross-check with your own criteria. If you have specific needs (brand-name only, a specific state of licensure, a particular price point), apply those filters to the tier candidates.
  5. Come back. The Watchlist is designed for repeat consultation. Bookmark it. Check it when your subscription comes up for renewal.

If you disagree with a score

Scores can be wrong, and we welcome corrections. If you believe a provider's score doesn't reflect reality — in either direction — send us a tip through the Tip Line. We'll re-review with the new information.

We especially welcome: tips about operational issues not yet in public record, compliance problems that haven't yet appeared in regulator action, internal information about pharmacy partners and clinical practices, and context about providers we may have missed. Whistleblower tips from inside the industry are treated confidentially.

The Watchlist as public good

The GLP-1 telehealth industry moves fast and markets itself aggressively. Asymmetric information favors providers. A neutral, continuously-updated scorecard is the counterweight. It helps individual patients choose, and it nudges the industry collectively toward transparency.

That is the theory. Whether the Watchlist lives up to it depends on how rigorous the methodology is, how current the data stays, and how useful readers actually find it. All three are ongoing projects. Comments, corrections, and accountability requests are welcome.

Head to the live Watchlist to see current scores for every major GLP-1 telehealth provider.

Not medical or legal advice. glp-1telemedicine.com investigates telehealth platforms as a journalism and consumer-protection project. Nothing here is medical advice, legal counsel, or a guarantee about any provider's current status. Regulatory actions, state laws, and company practices change; verify with primary sources (FDA, state medical boards, state pharmacy boards) before acting. Talk to a licensed clinician about your health and a licensed attorney about your rights.